SPY752.56+0.35%QQQ679.24+0.66%BTC/USD73,782.14+0.11%DIA523.25+0.29%GLD369.45+0.02%TLT80.86−0.02%

Premium Services

Premium Services

MDxHealth SA

MDXHNASDAQ

Trade with Public

Trade with Public

$0.1393

-0.0186-11.78%

Last update: Nov 10, 7:55 PM

Overview News Charts Earnings ForecastPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

MDxHealth (MDXH) Stock Price Target 2026 & Analyst Forecast - Benzinga

MDxHealth (MDXH) Stock Price Target 2026

The average analyst price target for MDxHealth is $4.38, 2920.7% above the current price. Of 4 analysts, 3 rate it Buy and 1 Hold. Targets range from $1.50 to $7. The latest change came on Oct 19, 2026, when BTIG downgraded MDxHealth from Buy to Neutral.

The Average Analyst Price Target for MDxHealth is $4.38.

Price Target Range — 5 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$4.38Upside to Avg. PT+2920.7%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for MDxHealth Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	BTIG	Mark Massaro	Downgrade	Buy→Neutral	—
Aug 21, 2026	BTIG	Mark Massaro	PT Cut	Buy	$4→$2
Aug 14, 2026	Lake Street	Thomas Flaten	PT Cut	Buy	$5→$3
May 14, 2026	Lake Street	Thomas Flaten	PT Cut	Buy	$9→$5
May 14, 2026	TD Cowen	Dan Brennan	PT Cut	Buy	$7→$2
May 14, 2026	BTIG	Mark Massaro	PT Cut	Buy	$7→$4
Dec 23, 2025	BTIG	Mark Massaro	Maintained	Buy	$7
Nov 13, 2025	TD Cowen	Dan Brennan	PT Raise	Buy	$5→$7
Nov 13, 2025	Lake Street	Thomas Flaten	PT Raise	Buy	$7→$9
Nov 13, 2025	BTIG	Mark Massaro	PT Raise	Buy	$6→$7
Nov 7, 2024	Piper Sandler	Jason Bednar	PT Cut	Overweight	$8→$6
Oct 31, 2024	Lake Street	—	Initiate	Buy	$7
Mar 7, 2024	Piper Sandler	Jason Bednar	PT Raise	Overweight	$6→$7
Mar 7, 2024	BTIG	Mark Massaro	PT Raise	Buy	$7→$8

Analyst Ratings News

PRO
BTIG Downgrades MDxHealth to Neutral

BTIG analyst Mark Massaro downgrades MDxHealth (NASDAQ:MDXH) from Buy to Neutral.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on MDxHealth, Lowers Price Target to $2

BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $4 to $2.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on MDxHealth, Lowers Price Target to $3

Lake Street analyst Thomas Flaten maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $5 to $3.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on MDxHealth, Lowers Price Target to $5

Lake Street analyst Thomas Flaten maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $9 to $5.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on MDxHealth, Lowers Price Target to $1.5

TD Cowen analyst Dan Brennan maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $7 to $1.5.

Benzinga Newsdesk

Apple To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday

Analyst ratings for top names changed: Doximity cut to neutral, National Vision lowered price target, Starbucks upgraded to buy, Commercial Metals raised to buy, Wix.Com target lowered, MDxHealth target slashed, Avalo Therapeutics target cut, Crowdstrike target raised.

Avi Kapoor